2022
DOI: 10.1017/s0033291722000058
|View full text |Cite
|
Sign up to set email alerts
|

Ameliorative patterns of grey matter in patients with first-episode and treatment-naïve schizophrenia

Abstract: Background Grey matter (GM) reduction is a consistent observation in established late stages of schizophrenia, but patients in the untreated early stages of illness display an increase as well as a decrease in GM distribution relative to healthy controls (HC). The relative excess of GM may indicate putative compensatory responses, though to date its relevance is unclear. Methods 343 first-episode treatment-naïve patients with schizophrenia (FES) and 342 HC were recruited. Multivariate so… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 53 publications
0
6
0
Order By: Relevance
“…The neuroanatomical differences between the two clusters varied across the three samples, possibly due to differences in recruitment criteria as well as the sample size differences, which combined with our stringent correction for multiple testing, reduced the likelihood of demonstrating significant regional differences in validation samples. Furthermore, the presence of stage-specific differences in the location of grey matter differences (i.e., the duration of illness effect) from age-and sex-matched healthy cohorts is a well-established finding in schizophrenia (Li et al, 2022;Palaniyappan, 2017). While scanning parameters varied across the three studies, it is important to note that both patients and healthy controls were scanned using the same acquisition parameters within each study.…”
Section: Discovery and Validation Of Two Thickness-based Subgroupsmentioning
confidence: 99%
“…The neuroanatomical differences between the two clusters varied across the three samples, possibly due to differences in recruitment criteria as well as the sample size differences, which combined with our stringent correction for multiple testing, reduced the likelihood of demonstrating significant regional differences in validation samples. Furthermore, the presence of stage-specific differences in the location of grey matter differences (i.e., the duration of illness effect) from age-and sex-matched healthy cohorts is a well-established finding in schizophrenia (Li et al, 2022;Palaniyappan, 2017). While scanning parameters varied across the three studies, it is important to note that both patients and healthy controls were scanned using the same acquisition parameters within each study.…”
Section: Discovery and Validation Of Two Thickness-based Subgroupsmentioning
confidence: 99%
“…34 These excesses appear as devi ations from healthy norms but occur in the presence of better outcomes or less illness burden (i.e., are apparently beneficial or compensatory). A subtle but statistically significant excess of grey matter concentration occurs among patients with consider ably short duration of psychotic illness, 35 which is associated with less severe symptoms and better cognitive profile among untreated patients. 35 Progressive supranormal deviations are also reported among adolescents with subthreshold symptoms for neurodevelopmental markers such as gyrification, 36 a fea ture that may relate to better prognosis at later stages.…”
Section: Grey Matter Enrichment In Schizophreniamentioning
confidence: 99%
“…If we assume schizophrenia as a disorder that involves some degree of illness-related brain changes, then concomitant adaptive changes in response to this deficit should be expected, at least in a subset of patients [101,102]. Some of these adaptive changes, in effect, may obscure the construct-to-circuit relationship between the LN and FTD.…”
Section: Issue 6: Compensatory Neural Changesmentioning
confidence: 99%